Tislelizumab (BGB-A317)
BGB-A317-209
Phase 2 small_molecule active
Quick answer
Tislelizumab (BGB-A317) for MSI-H/dMMR Solid Tumors is a Phase 2 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- MSI-H/dMMR Solid Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active